Companies › Sanofi
34 active drug programs in 145 registered trials: 50 Phase 3, 42 Phase 2, 36 Phase 1, 17 Phase 4; Infectious disease, Vaccines, Metabolic and endocrine, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Ma Recombinant spike protein vaccine with Matrix-M adjuvant targeting SARS-CoV-2 Omicron subv | – | Phase 4 | COVID-19; Yellow Fever Immunization | Nov 2026 |
| H5 Flu IMP 1 Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor | ROCK2, ROCK1, TNFSF4, CD38, IL4R | Phase 4 | RSV Immunization; Diabetes Mellitus, Type 1; Asthma; Dermatitis Atopic … | Dec 2026 |
| Avalglucosidase alfa (GZ402666) Lysosomal acid alpha-glucosidase (GAA) replacement therapy | GAA | Phase 4 | Glycogen Storage Disease Type II; Glycogen Storage Disease Type II-Pompe's Disease; Glycogen Storage Disease Type II Late Onset | Jun 2027 |
| Insulin Glargine Insulin receptor agonist | INSR | Phase 4 | Type 2 Diabetes (T2D); Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Type 2 Diabetes … | – |
| rilzabrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Immune Thrombocytopenia; Sickle Cell Disease; Autoimmune Haemolytic Anaemia; Immunoglobulin G4 Related Disease … | Nov 2026 |
| SAR441344 (Frexalimab) | – | Phase 3 | Multiple Sclerosis; Systemic Lupus Erythematosus; Focal Segmental Glomerulosclerosis; Type 1 Diabetes Mellitus … | Nov 2026 |
| PCV21 vaccine 21-valent pneumococcal conjugate vaccine | – | Phase 3 | Pneumococcal Infections; Pneumococcal Immunization | Dec 2026 |
| Venglustat (GZ402671) Ceramide glucosyltransferase inhibitor | UGCG | Phase 3 | Gaucher's Disease Type III; Fabry Disease | Jan 2027 |
| PCV21 vaccine 21-valent pneumococcal conjugate vaccine | – | Phase 3 | Sickle Cell Disease; Pneumococcal Immunization | Jan 2027 |
| Itepekimab (SAR440340) Interleukin-33 inhibitor | IL33 | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | Feb 2027 |
| Lunsekimig (SAR443765) IL-5 receptor alpha antagonist | IL5RA | Phase 3 | Chronic Obstructive Pulmonary Disease; Asthma; Chronic Rhinosinusitis With Nasal Polyps | Jun 2027 |
| Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugat Tetanus toxoid conjugate vaccine against meningococcal serogroups A, C, W, and Y | – | Phase 3 | Meningococcal Immunisation | Dec 2027 |
| Sarilumab (SAR153191) Interleukin-6 receptor alpha subunit antagonist | IL6R | Phase 3 | Polymyalgia Rheumatica; Juvenile Idiopathic Arthritis; Rheumatoid Arthritis; Melanoma … | Mar 2028 |
| MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Tox Quadrivalent meningococcal conjugate vaccine targeting serogroups A, C, W, and Y conjugate | – | Phase 3 | Meningococcal Infection | Mar 2028 |
| Tolebrutinib (SAR442168) Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Relapsing Multiple Sclerosis | Apr 2029 |
| Fitusiran Antithrombin mRNA RNAi inhibitor | SERPINC1 | Phase 3 | Hemophilia | – |
| MenACYW conjugate vaccine (MenQuadfi) Quadrivalent meningococcal conjugate vaccine targeting serogroups A, C, Y, W | – | Phase 3 | Meningococcal Infection | – |
| SAR442970 (brivekimig) | – | Phase 2 | Ulcerative Colitis; Crohn's Disease; Focal Segmental Glomerulosclerosis; Hidradenitis Suppurativa … | Dec 2026 |
| vYF vaccine (produced on serum-free Vero cells) Live attenuated yellow fever virus vaccine | – | Phase 2 | Yellow Fever; Yellow Fever Vaccine | Apr 2027 |
| SAR447537 (INBRX-101) Recombinant bivalent Fc fusion protein targeting alpha-1 antitrypsin deficiency | – | Phase 2 | Alpha 1-Antitrypsin Deficiency | Jun 2028 |
| Bivalent RSV+HMPV protein vaccine (RPF08203) Respiratory syncytial virus and human metapneumovirus protein vaccine | RSVA, RSVB, HMPV | Phase 2 | Respiratory Syncytial Virus | Jul 2028 |
| BIVV020 (SAR445088) Neonatal Fc receptor (FcRn) antagonist | FCGRT | Phase 2 | Transplant Rejection | – |
| Pandemic flu H5 HA mRNA SD2 vaccine mRNA vaccine encoding H5 hemagglutinin | HA | Phase 1 | Pandemic Influenza Immunization | Dec 2026 |
| Investigational hMPV/RSV vaccine mRNA vaccine encapsulated in lipid nanoparticle targeting hMPV and RSV | HMPV, RSV | Phase 1 | Human Metapneumovirus Immunization | Jan 2027 |
| H5 Flu IMP 2 mRNA vaccine encoding H5 hemagglutinin antigen | – | Phase 1 | Respiratory Syncytial Virus (RSV) | Apr 2027 |
| H5 Flu IMP 3 mRNA vaccine encoding H5 hemagglutinin antigen | – | Phase 1 | Respiratory Syncytial Virus (RSV) | Apr 2027 |
| RSV IMP 4 mRNA vaccine encoding RSV antigen | – | Phase 1 | Respiratory Syncytial Virus (RSV) | Apr 2027 |
| Pentavalent Meningococcal ABCYW vaccine Conjugate vaccine against Neisseria meningitidis serogroups A, B, C, Y, and W | – | Phase 1 | Meningococcal Immunization | May 2027 |
| Pegenzileukin IL-2R beta/gamma agonist | IL2RG, IL2RB | Phase 1 | Plasma Cell Myeloma Refractory | Sep 2027 |
| Chlamydia mRNA Vaccine mRNA vaccine targeting Chlamydia trachomatis | – | Phase 1 | Chlamydia Trachomatis Immunization | Nov 2027 |
| SAR448501/DR-0201 Bispecific antibody targeting CD19 and CD3E | CD19, CD3E | Phase 1 | B-cell Non Hodgkin Lymphoma; Systemic Lupus Erythematosus (SLE) | Jan 2028 |
| Flu H5 egg pandemic low dose vaccine with adjuvant Matrix-M H5N8 influenza vaccine with Matrix-M adjuvant | – | Phase 1 | Healthy Volunteers | Feb 2028 |
| RSV + HMPV Candidate Vaccine Live attenuated or recombinant viral vaccine against respiratory syncytial virus and human | RSV, HMPV | Phase 1 | Respiratory Syncytial Virus Immunization | May 2028 |
| Acne mRNA vaccine mRNA vaccine | – | Phase 1 | Acne | Nov 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05222906 | Venglustat (GZ402671) | Phase 3 | Gaucher's Disease Type III | Metabolic and endocrine | Oct 2025 |
| NCT05156710 | BIVV020 (SAR445088) | Phase 2 | Transplant Rejection | Other | Oct 2025 |
| NCT07135986 | MenACYW conjugate vaccine (MenQuadfi) | Phase 3 | Meningococcal Infection | Infectious disease | May 2026 |
| NCT07109297 | H5 Flu IMP 1 | Phase 4 | RSV Immunization | Vaccines | Jun 2026 |
| NCT07274644 | Insulin Glargine | Phase 4 | Metabolic Dysfunction-Associated Steatotic Liver Disease | Metabolic and endocrine | Jun 2026 |
| NCT06637631 | H5 Flu IMP 1 | Phase 2 | Crohn's Disease | Immunology | Jul 2026 |
| NCT06867094 | H5 Flu IMP 1 | Phase 2 | Colitis Ulcerative | Immunology | Aug 2026 |
| NCT05757713 | H5 Flu IMP 1 | Phase 4 | Diabetes Mellitus, Type 1 | Metabolic and endocrine | Aug 2026 |
| NCT03754790 | Fitusiran | Phase 3 | Hemophilia | Hematology | Sep 2026 |
| NCT06671587 | Insulin Glargine | Phase 4 | Type 2 Diabetes (T2D) | Metabolic and endocrine | Sep 2026 |
| NCT06033833 | H5 Flu IMP 1 | Phase 2 | Asthma | Respiratory | Sep 2026 |
| NCT07222189 | H5 Flu IMP 1 | Phase 2 | Colitis Ulcerative | Immunology | Sep 2026 |
| NCT07646548 | H5 Flu IMP 1 | Phase 1 | Healthy Volunteers | Other | Sep 2026 |
| NCT07855250 | rilzabrutinib | Phase 1 | Healthy Volunteer | Other | Nov 2026 |
| NCT05039840 | SAR441344 (Frexalimab) | Phase 2 | Systemic Lupus Erythematosus | Immunology | Nov 2026 |
| NCT07861542 | Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Ma | Phase 4 | COVID-19 | Infectious disease | Nov 2026 |
| NCT07103148 | Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Ma | Phase 3 | Yellow Fever Immunization | Vaccines | Nov 2026 |
| NCT07216079 | rilzabrutinib | Phase 3 | Immune Thrombocytopenia | Hematology | Nov 2026 |
| NCT06838000 | PCV21 vaccine | Phase 3 | Pneumococcal Infections | Infectious disease | Dec 2026 |
| NCT06907511 | Pandemic flu H5 HA mRNA SD2 vaccine | Phase 1 | Pandemic Influenza Immunization | Vaccines | Dec 2026 |
| NCT05588843 | H5 Flu IMP 1 | Phase 2 | Colitis Ulcerative | Immunology | Dec 2026 |
| NCT04128995 | Insulin Glargine | Phase 4 | Diabetes Mellitus, Type 2 | Metabolic and endocrine | Dec 2026 |
| NCT06975722 | SAR442970 (brivekimig) | Phase 2 | Ulcerative Colitis | Immunology | Dec 2026 |
| NCT06958536 | SAR442970 (brivekimig) | Phase 2 | Crohn's Disease | Immunology | Dec 2026 |
| NCT06500702 | rilzabrutinib | Phase 2 | Focal Segmental Glomerulosclerosis | Genitourinary | Dec 2026 |
| NCT06500702 | SAR442970 (brivekimig) | Phase 2 | Focal Segmental Glomerulosclerosis | Genitourinary | Dec 2026 |
| NCT06500702 | SAR441344 (Frexalimab) | Phase 2 | Focal Segmental Glomerulosclerosis | Genitourinary | Dec 2026 |
| NCT06619301 | Insulin Glargine | Phase 3 | Diabetes Mellitus in Pregnancy | Metabolic and endocrine | Jan 2027 |
| NCT05206773 | Venglustat (GZ402671) | Phase 3 | Fabry Disease | Metabolic and endocrine | Jan 2027 |
| NCT07247188 | PCV21 vaccine | Phase 3 | Sickle Cell Disease | Hematology | Jan 2027 |
| NCT06686654 | Investigational hMPV/RSV vaccine | Phase 1 | Human Metapneumovirus Immunization | Infectious disease | Jan 2027 |
| NCT06686654 | Investigational hMPV/RSV vaccine | Phase 1 | Human Metapneumovirus Immunization | Infectious disease | Jan 2027 |
| NCT06686654 | Investigational hMPV/RSV vaccine | Phase 1 | Human Metapneumovirus Immunization | Infectious disease | Jan 2027 |
| NCT06686654 | Investigational hMPV/RSV vaccine | Phase 1 | Human Metapneumovirus Immunization | Infectious disease | Jan 2027 |
| NCT05584670 | H5 Flu IMP 1 | Phase 1 | Solid Tumor | Oncology | Jan 2027 |
| NCT07170917 | SAR442970 (brivekimig) | Phase 2 | Hidradenitis Suppurativa | Immunology | Feb 2027 |
| NCT06984627 | rilzabrutinib | Phase 2 | Graves' Disease | Metabolic and endocrine | Feb 2027 |
| NCT07424144 | Itepekimab (SAR440340) | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | Respiratory | Feb 2027 |
| NCT06834360 | Itepekimab (SAR440340) | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | Respiratory | Feb 2027 |
| NCT05731128 | H5 Flu IMP 1 | Phase 2 | Colitis Ulcerative | Immunology | Feb 2027 |
| NCT05097287 | H5 Flu IMP 1 | Phase 4 | Asthma | Respiratory | Mar 2027 |
| NCT06407934 | H5 Flu IMP 1 | Phase 3 | Dermatitis Atopic | Immunology | Mar 2027 |
| NCT05662319 | H5 Flu IMP 1 | Phase 3 | Hemophilia | Hematology | Mar 2027 |
| NCT06834347 | Itepekimab (SAR440340) | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | Respiratory | Mar 2027 |
| NCT06356571 | H5 Flu IMP 1 | Phase 2 | Plasma Cell Myeloma Refractory | Oncology | Apr 2027 |
| NCT07516418 | H5 Flu IMP 1 | Phase 1 | Respiratory Syncytial Virus (RSV) | Infectious disease | Apr 2027 |
| NCT07516418 | H5 Flu IMP 2 | Phase 1 | Respiratory Syncytial Virus (RSV) | Infectious disease | Apr 2027 |
| NCT07516418 | H5 Flu IMP 3 | Phase 1 | Respiratory Syncytial Virus (RSV) | Infectious disease | Apr 2027 |
| NCT07516418 | RSV IMP 4 | Phase 1 | Respiratory Syncytial Virus (RSV) | Infectious disease | Apr 2027 |
| NCT03319667 | H5 Flu IMP 1 | Phase 3 | Plasma Cell Myeloma | Oncology | Apr 2027 |
| NCT07156175 | H5 Flu IMP 1 | Phase 2 | Microscopic Colitis | Immunology | Apr 2027 |
| NCT07853131 | rilzabrutinib | Phase 1 | Renal Impairment | Genitourinary | Apr 2027 |
| NCT05011123 | vYF vaccine (produced on serum-free Vero cells) | Phase 2 | Yellow Fever | Infectious disease | Apr 2027 |
| NCT07295028 | H5 Flu IMP 1 | Phase 1 | Lower Respiratory Tract Disease | Respiratory | Apr 2027 |
| NCT06111586 | SAR441344 (Frexalimab) | Phase 2 | Type 1 Diabetes Mellitus | Metabolic and endocrine | Apr 2027 |
| NCT05983068 | H5 Flu IMP 1 | Phase 4 | Dermatitis Atopic | Immunology | Apr 2027 |
| NCT06812988 | SAR442970 (brivekimig) | Phase 2 | Type 1 Diabetes Mellitus | Metabolic and endocrine | Apr 2027 |
| NCT04333706 | Sarilumab (SAR153191) | Phase 1 | Breast | Oncology | May 2027 |
| NCT06141473 | SAR441344 (Frexalimab) | Phase 3 | Multiple Sclerosis | Neurology | May 2027 |
| NCT06556147 | H5 Flu IMP 1 | Phase 1 | Healthy Volunteers | Other | May 2027 |
The 60 nearest readouts of 145 trials; the rest in the app.
Cash and short-term investments of 8.4bn EUR on 2025-12-31; operating cash flow positive
HMPV (3) BTK (2) RSV (2) FCGRT (1) CD19 (1) CD3E (1) IL33 (1) RSVA (1) RSVB (1) IL5RA (1) IL2RG (1) IL2RB (1)
Johnson & Johnson (Janssen) AstraZeneca Roche Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Amgen ModernaTX Allogene Therapeutics Miltenyi Biomedicine
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.